Roche Adds Non-Invasive Prenatal Testing to Pipeline with Ariosa Acquisition

Roche announced on Dec. 2, 2014 the acquisition of Ariosa Diagnostics, a US-based molecular diagnostics company providing highly-targeted, non-invasive prenatal testing (NIPT) using cell-free DNA (cfDNA) technology. The transaction is expected to close in December 2014.

Ariosa s blood testOriginal Article